当前位置: 首页 > 期刊 > 《中国医学创新》 > 2025年第2期
编号:2263889
精氨酸加压素在孤独症谱系障碍社会交往障碍患儿中的研究进展
http://www.100md.com 2025年2月7日 中国医学创新 2025年第2期
     【摘要】 孤独症谱系障碍(ASD)是一种异质性神经发育障碍性疾病。至今为止,发病机制未明,其早期表现为普遍存在的社交缺陷和沟通障碍,并伴有重复性刻板行为。目前无特定针对性治疗药物。精氨酸加压素(AVP)不仅与水盐平衡和应激轴调节有关,还与社会行为有关,因此在ASD研究领域,AVP作为一种潜在的治疗方案,越来越受到人们的关注。本文对国内外文献研究AVP在ASD社会交往中异常表现的相关研究进行综述。在本文中,探讨了AVP可能成为ASD的诊断性生物标志物及AVP系统具有改善ASD社会功能特征的潜力,希望本综述能为ASD社会交往障碍的临床诊治提供思路。

    【关键词】 孤独症谱系障碍 精氨酸加压素 社会交往障碍

    Research Progress of Arginine Vasopressin in Children with Autism Spectrum Disorder and Social Interaction Disorder/WEI Suwen, LI Ruishi, HE Si, FENG Zhaocai. //Medical Innovation of China, 2025, 22(02): -165

    [Abstract] Autism spectrum disorder (ASD) is a heterogeneous neuro developmental disorder. Up to now, the pathogenesis is not clear, and its early manifestations are widespread social defects and communication disorders, accompanied by repetitive stereotyped behavior. At present, there are no specific targeted therapeutic drugs. Arginine Vasopressin (AVP) is not only related to water-salt balance and stress axis regulation, but also related to social behavior. Therefore, in the field of ASD research, AVP as a potential treatment has attracted more and more attention. In this paper ......

您现在查看是摘要页,全文长 18007 字符